75 institutions hold shares in Aytu Biopharma Inc. (AYTU), with 1.4M shares held by insiders accounting for 7.80% while institutional investors hold 23.57% of the company’s shares. The shares outstanding are 23.47M, and float is at 14.28M with Short Float at 12.95%. Institutions hold 21.73% of the Float.
The top institutional shareholder in the company is Stonepine Capital Management, LLC with over 1.4 million shares valued at $8.36 million. The investor’s holdings represent 5.96% of the AYTU Shares outstanding. As of Dec 30, 2020, the second largest holder is Armistice Capital, LLC with 1.33 million shares valued at $7.97 million to account for 5.68% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 0.7 million shares representing 2.96% and valued at over $4.16 million, while Blackrock Inc. holds 1.31% of the shares totaling 0.31 million with a market value of $1.83 million.
Aytu Biopharma Inc. (NASDAQ: AYTU) is 14.05% higher on its value in year-to-date trading and has touched a low of $5.86 and a high of $20.00 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The AYTU stock was last observed hovering at around $6.75 in the last trading session, with the day’s gains setting it 0.07% off its average median price target of $17.50 for the next 12 months. It is also 71.58% off the consensus price target high of $24.00 offered by 2 analysts, but current levels are 38.0% higher than the price target low of $11.00 for the same period.
Currently trading at $6.82, the stock is -1.54% and -11.66% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.24 million and changing 1.04% at the moment leaves the stock -28.88% off its SMA200. AYTU registered -61.25% loss for a year compared to 6-month loss of -33.14%. The firm has a 50-day simple moving average (SMA 50) of $7.63 and a 200-day simple moving average (SMA200) of $8.12.
The stock witnessed a -8.95% gain in the last 1 month and extending the period to 3 months gives it a -13.56%, and is 0.89% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.66% over the week and 5.08% over the month.
Aytu Biopharma Inc. (AYTU) has around 75 employees, a market worth around $156.79M and $51.70M in sales. Profit margin for the company is -43.20%. Distance from 52-week low is 16.38% and -65.90% from its 52-week high.
Aytu Biopharma Inc. (AYTU) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Aytu Biopharma Inc. (AYTU) is a “Buy”. 2 analysts offering their recommendations for the stock have an average rating of 1.50, where 0 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Aytu Biopharma Inc. is expected to release its quarterly report on 09/02/2021 and quarterly earnings per share for the current quarter are estimated at -$0.35 with sales reaching $13.98M over the same period.The EPS is expected to grow by 91.30% this year, but quarterly earnings will post 115.70% year-over-year.
Aytu Biopharma Inc. (AYTU) Insider Activity
A total of 10 insider transactions have happened at Aytu Biopharma Inc. (AYTU) in the last six months, with sales accounting for 0 and purchases happening 10 times. The most recent transaction is an insider purchase by ARMISTICE CAPITAL, LLC, the company’s Director. SEC filings show that ARMISTICE CAPITAL, LLC bought 1,333,334 shares of the company’s common stock on Dec 11 at a price of $6.00 per share for a total of $8.0 million. Following the purchase, the insider now owns 1.33 million shares.